Screener
AbCellera Biologics Inc. ABCL Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: AbCellera Biologics Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:28 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001703057-26-000046
FAQ
- What is AbCellera Biologics Inc.'s total liabilities?
- AbCellera Biologics Inc. (ABCL) reported total liabilities of $411.56M in Q2 2026.
- How has AbCellera Biologics Inc.'s total liabilities changed year-over-year?
- AbCellera Biologics Inc.'s total liabilities increased by 4.2% year-over-year, from $394.99M to $411.56M.
- What is the long-term trend for AbCellera Biologics Inc.'s total liabilities?
- Over 5 years (2020 to 2025), AbCellera Biologics Inc.'s total liabilities has grown at a 17.4% compound annual growth rate (CAGR), from $175.03M to $390.05M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about AbCellera Biologics Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude